This antibody was shown to bind to CCR7-expressing DCs, although not exclusively [59], and to impair the migratory capacity of cells obtained from CLL patients [60], opening the possibility to also exploit this signalling pathway in allergic patients. This evidence concerns the gene CCR7 and B-cell chronic lymphocytic leukemia.